Taysha Gene Therapies Research and Development Expenses 2020-2026 | TSHA
Taysha Gene Therapies research and development expenses from 2020 to 2026. Research and development expenses can be defined as an expense arising from studies and product development processes.
|
Taysha Gene Therapies Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025 | $86 |
| 2024 | $66 |
| 2023 | $57 |
| 2022 | $91 |
| 2021 | $132 |
| 2020 | $32 |
| 2019 | $0 |
|
Taysha Gene Therapies Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $34 |
| 2025-12-31 | $25 |
| 2025-09-30 | $26 |
| 2025-06-30 | $20 |
| 2025-03-31 | $16 |
| 2024-12-31 | $15 |
| 2024-09-30 | $15 |
| 2024-06-30 | $15 |
| 2024-03-31 | $21 |
| 2023-12-31 | $13 |
| 2023-09-30 | $12 |
| 2023-06-30 | $20 |
| 2023-03-31 | $13 |
| 2022-12-31 | $13 |
| 2022-09-30 | $17 |
| 2022-06-30 | $24 |
| 2022-03-31 | $38 |
| 2021-12-31 | $38 |
| 2021-09-30 | $40 |
| 2021-06-30 | $31 |
| 2021-03-31 | $24 |
| 2020-12-31 | $12 |
| 2020-09-30 | $11 |
| 2020-06-30 | $3 |
| 2020-03-31 | $6 |
| 2019-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.290B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |